COSCIENS Biopharma Total Assets

COSCIENS Biopharma posts a total assets of $50M as of June 2024. That compares with $46M in the prior-year period — up 7.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, COSCIENS Biopharma's total assets was $46M. The latest reading is $50M — a 7.7% year-over-year increase (period ending June 2024). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of COSCIENS Biopharma's financial statement story. At $50M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AEZS's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; COSCIENS Biopharma's other metric pages and overview cover the third.

Judging COSCIENS Biopharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $50M here, then scan peer and history charts to see if the gap is persistent.